The use of tranexamic acid (TXA) has markedly increased since the results of the CRASH-II trial were published. In addition to its use in trauma, TXA has been evaluated and used in numerous other conditions, including post-partum hemorrhage and epistaxis. Recently, the HALT-IT Trial was published online in the Lancet, which evaluated the use of TXA in patients with acute gastrointestinal bleeding. In this podcast we discuss the HALT-IT Trial and its implications for clinical practice.
You can get CME credit for this episode here!Click here for CME Account Creation Instructions
It’s time for our annual literature update of the best and most discussed articles from 2016! Simply a great discussion on important topics such...
In this podcast we complete our discussion of articles from the 2017 emergency medicine and critical care literature that have potential practice changing implications. ...
More than 200,000 patients per year undergo coronary artery bypass graft (CABG) surgery. Up to 20 percent of these patients will require readmission within...
